1. Home
  2. RRR vs PBLS Comparison

RRR vs PBLS Comparison

Compare RRR & PBLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Red Rock Resorts Inc.

RRR

Red Rock Resorts Inc.

HOLD

Current Price

$64.23

Market Cap

3.9B

ML Signal

HOLD

Logo Parabilis Medicines Inc. Common Stock

PBLS

Parabilis Medicines Inc. Common Stock

N/A

Current Price

$30.01

Market Cap

3.6B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
RRR
PBLS
Founded
1976
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Hotels/Resorts
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.9B
3.6B
IPO Year
2015
2026

Fundamental Metrics

Financial Performance
Metric
RRR
PBLS
Price
$64.23
$30.01
Analyst Decision
Strong Buy
Analyst Count
13
0
Target Price
$69.69
N/A
AVG Volume (30 Days)
696.6K
545.1K
Earning Date
04-29-2026
N/A
Dividend Yield
3.64%
N/A
EPS Growth
23.32
N/A
EPS
0.73
N/A
Revenue
$2,011,483,000.00
N/A
Revenue This Year
$3.41
N/A
Revenue Next Year
$4.62
N/A
P/E Ratio
$88.96
N/A
Revenue Growth
3.74
N/A
52 Week Low
$50.52
$25.56
52 Week High
$68.99
$33.65

Technical Indicators

Market Signals
Indicator
RRR
PBLS
Relative Strength Index (RSI) 54.16 56.09
Support Level $59.81 $26.96
Resistance Level $68.55 $30.90
Average True Range (ATR) 1.92 2.47
MACD -0.28 -0.11
Stochastic Oscillator 40.40 51.59

Price Performance

Historical Comparison
RRR
PBLS

About RRR Red Rock Resorts Inc.

Red Rock Resorts Inc along with its subsidiary is a gaming, development and management company that develops and operates strategically-located casino and entertainment properties. Its casino properties are conveniently located throughout the Las Vegas valley and provide its customers a wide variety of entertainment and dining options. The majority of revenue is derived from Casinos, followed by Food and Beverages, Rooms and others.

About PBLS Parabilis Medicines Inc. Common Stock

Parabilis Medicines Inc s a clinical-stage biopharmaceutical company. It is focused on the development of medicines targeting protein interactions associated with human diseases. It uses a proprietary platform to develop stabilized helical peptide therapeutics, referred to as Helicons, designed to bind and modulate specific proteins. Its flagship product candidate, zolucatetide, targets the interaction between β-catenin and the T-cell factor (TCF) family of transcription factors within the Wnt/β-catenin signaling pathway, which is associated with cell proliferation and differentiation in multiple cancer types.

Share on Social Networks: